ConductScience.org, home

Paper32192573

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.

Davis KL and 10 others. Lancet Oncol, 2020. Cited by 281 papers, by iCite.

Cite this record

ConductScience Library. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Papers, record 32192573. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32192573

Download JSON
Disease
melanoma589 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
PubMed
Journal
Lancet Oncol
PubMed
Year
2020
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
281
iCite
Relative citation ratio, by iCite
11.9
iCite
Revised in PubMed
2021-04-02
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Davis KLKara L
2Fox EElizabeth
3Merchant MSMelinda S
4Reid JMJoel M
5Kudgus RARachel A
6Liu XXiaowei
7Minard CGCharles G
8Voss SStephan
9Berg SLStacey L
10Weigel BJBrenda J
11Mackall CLCrystal L

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
Hodgkin DiseaseMajor topic
Lymphoma, Non-HodgkinMajor topic
Neoplasm Recurrence, LocalMajor topic
NeoplasmsMajor topic
NivolumabMajor topic
Adolescent
Adult
Child
Child, Preschool
Female
Humans
Infant
Male
Response Evaluation Criteria in Solid Tumors
Young Adult

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA015083NCI NIH HHSUnited StatesP30CA015083PubMed and NIHNIH RePORTER
UM1 CA228823NCI NIH HHSUnited StatesUM1CA228823PubMed and NIHNIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02304458Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasDerived from the trialYesClinicalTrials.gov
NCT05395741Regorafenib in Patients With Refractory Primary Bone TumorsResultsClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in32192574Nivolumab in paediatric cancer: children are not little adults.https://conductscience.org/library/papers/32192574

Source PubMed

Download CSV of comments and corrections

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
229606586Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Lancet Oncol2018https://conductscience.org/library/papers/29606586PubMed
327451390Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.Lancet Oncol2016https://conductscience.org/library/papers/27451390PubMed
428408462Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.Blood2017https://conductscience.org/library/papers/28408462PubMed
527001570Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.J Clin Oncol2016https://conductscience.org/library/papers/27001570PubMed
625327979The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.Pediatr Blood Cancer2015https://conductscience.org/library/papers/25327979PubMed
728787259Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.J Clin Oncol2017https://conductscience.org/library/papers/28787259PubMed
829466156Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.N Engl J Med2018https://conductscience.org/library/papers/29466156PubMed
924853691Declining childhood and adolescent cancer mortality.Cancer2014https://conductscience.org/library/papers/24853691PubMed
1027998223Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.J Clin Oncol2016https://conductscience.org/library/papers/27998223PubMed
1130160041Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency.Pediatr Blood Cancer2018https://conductscience.org/library/papers/30160041PubMed
1219171710Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma.J Clin Oncol2009https://conductscience.org/library/papers/19171710PubMed
1318276034A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation.Comput Methods Programs Biomed2008https://conductscience.org/library/papers/18276034PubMed
1428490569Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.Blood2017https://conductscience.org/library/papers/28490569PubMed
1526317305Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.Appl Immunohistochem Mol Morphol2015https://conductscience.org/library/papers/26317305PubMed
162702835Optimal two-stage designs for phase II clinical trials.Control Clin Trials1989https://conductscience.org/library/papers/2702835PubMed
1725319501T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet2015https://conductscience.org/library/papers/25319501PubMed
1822658127Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med2012https://conductscience.org/library/papers/22658127PubMed
1928019091Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.CPT Pharmacometrics Syst Pharmacol2017https://conductscience.org/library/papers/28019091PubMed
2027928714Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.Invest New Drugs2017https://conductscience.org/library/papers/27928714PubMed

See all 33 referencesDownload CSV of references

Cited by221

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 281 citations.

PMIDTitleJournalYearIn PapersSource
42964569Artificial intelligence-enabled nursing surveillance for pediatric cancer immunotherapy: integrating biomarkers, patient-reported outcomes, and long-term toxicity management.Front Med (Lausanne)2026https://conductscience.org/library/papers/42964569PubMed
42952771Hypoxic conditioning of neuroblastoma cells promotes CD8+ T-cell dysfunction through the HIF-1α/PD-L1 axis.Front Pediatr2026https://conductscience.org/library/papers/42952771PubMed
42920922Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies.Front Med (Lausanne)2026https://conductscience.org/library/papers/42920922PubMed
42776062The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.Clin Cancer Res2026https://conductscience.org/library/papers/42776062PubMed
42666611Treatment strategies for relapsed/refractory hemophagocytic lymphohistiocytosis in pediatric patients.Ther Adv Hematol2026https://conductscience.org/library/papers/42666611PubMed
42618937Recurrent Mandibular Ewing sarcoma in an 11-year-old boy: a rare pediatric case and review of the literature.J Med Case Rep2026https://conductscience.org/library/papers/42618937PubMed
42613365Paediatric therapeutic development workshop on osteosarcoma.Br J Cancer2026https://conductscience.org/library/papers/42613365PubMed
42547980Translational perspectives on immunotherapy targets, germline syndromes, and novel fusions.Oncologist2026https://conductscience.org/library/papers/42547980PubMed
42496364Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non-Clinical Evidence, and Regulatory Science.J Clin Pharmacol2026https://conductscience.org/library/papers/42496364PubMed
42441182Endocrine dysfunction induced by anti-PD-1 antibody and tyrosine kinase inhibitor in a pediatric patient with renal cell carcinoma.Clin Pediatr Endocrinol2026https://conductscience.org/library/papers/42441182PubMed
42292421Metabolic-immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities.Front Immunol2026https://conductscience.org/library/papers/42292421PubMed
42288687Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.Br J Cancer2026https://conductscience.org/library/papers/42288687PubMed
42268572Pediatric Melanoma: Emerging Therapies and Ongoing Clinical Trials.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/42268572PubMed
42237783Immune checkpoint therapy in pediatric and adolescent lymphomas.Haematologica2026https://conductscience.org/library/papers/42237783PubMed
42222420Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.Front Oncol2026https://conductscience.org/library/papers/42222420PubMed
42212138Dynamic changes in peripheral blood lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in metastatic osteosarcoma.Front Immunol2026https://conductscience.org/library/papers/42212138PubMed
42179886Immunotherapy and postoperative bone defect repair strategies based on osteosarcoma tumor microenvironment characteristics: balancing antitumor effects and promotion of bone regeneration.Regen Biomater2026https://conductscience.org/library/papers/42179886PubMed
42171699The role of immunotherapy in the treatment of neuroblastoma.Surg Today2026https://conductscience.org/library/papers/42171699PubMed
42142195Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?J Neurooncol2026https://conductscience.org/library/papers/42142195PubMed
42091739New biological insights into osteosarcoma-lessons from single cell sequencing studies.Cancer Metastasis Rev2026https://conductscience.org/library/papers/42091739PubMed

See all 221 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
IPILIMUMABCHEMBL1789844Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1789844ChEMBL
REGORAFENIBCHEMBL1946170Results1https://conductscience.org/library/drugs/CHEMBL1946170ChEMBL
NIVOLUMABCHEMBL2108738Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2108738ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32192573

GET https://conductscience.org/api/papers/v1/32192573/references?page=2